Vaccines Market Worth 48.03 Billion USD by 2021
PUNE, India, August 9, 2016 /PRNewswire/ --
According to a new market research report "Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Inactivated & Subunit, Recombinant), Disease Indication (Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), End User (Pediatrics, Adults) & Type - Forecasts to 2021", published by MarketsandMarkets, The global market is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021.
(Logo: http://photos.prnewswire.com/prnh/20160303/792302 )
Browse 89 market data Tables and 55 Figures spread through 158 Pages and in-depth TOC on "Vaccines Market"
http://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html
Early buyers will receive 10% customization on this report.
The major factor driving the growth of this market are high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs.
The report segments this market based on technology, type, disease indication, end-users, and regions. Among the various technologies, the conjugate vaccines segment is expected to account for the largest share of the market. This segment is projected to grow at the highest CAGR from 2016 to 2021. The high growth of this segment can be attributed to the increasing government support for vaccine development and rising company investments.
Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=1155
On the basis of type, the Vaccines Market is segmented into monovalent vaccines and multivalent vaccines. The monovalent vaccines segment is expected to account for the largest share of the global Vaccines Market in 2016 due to rising prevalence of diseases and increasing government and non-government initiatives for vaccine R&D activities.
Disease indication, included in the Vaccines Market are pneumococcal disease, influenza, diphtheria, tetanus, and pertussis (DTP), hepatitis, rotavirus, varicella, meningococcal disease, polio, measles, mumps, and rubella (MMR), human papilloma virus (HPV) infection, and others. The pneumococcal disease segment is expected to account for the largest share of the global Vaccines Market in 2016. High incidence of pneumococcal infections is driving the growth of this market.
End-users, included in the Vaccines Market are pediatrics and adults. The pediatrics segment is expected to account for the largest share of the global Vaccines Market in 2016. Increasing prevalence of diseases in children and rising number of awareness programs to promote vaccination will drive the growth of this market.
Based on regions, the global Vaccines Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this segment is driven by increasing government funding for vaccine research and immunization.
Key players in the Vaccines Market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Merck & Co. (U.S.), Pfizer, Inc. (U.S.), Sanofi Pasteur (France), and Serum Institute of India Pvt. Ltd. (India).
Browse Related Reports:
Veterinary / Animal Vaccines Market by Product (Livestock, Companion, Poultry, Equine, Porcine), Diseases (Rabies, Distemper, Foot & Mouth, Gumboro, Swine& Avian Influenza, Strangles) & Technology (Live attenuated, DNA, Inactivated) - Global Forecast to 2020.
http://www.marketsandmarkets.com/Market-Reports/animal-veterinary-vaccines-market-1233.html
Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021.
http://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html
About MarketsandMarkets:
MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Contact:
Mr. Rohan
Unit No. 802, 8th Floor,
Tower - 7, Magarpatta City SEZ,
Hadapsar, Pune - 411013,
Maharashtra, India.
Tel: +1-888-6006-441.
Email: [email protected]
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
SOURCE MarketsandMarkets
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article